Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312286 · ClinicalTrials.gov registry record · Phase 2
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 538
- Enrollment target
NCT00312286: Clinical Trial Phase 2 study, sponsored by Takeda.
NCT00312286 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 538 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (305% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00312286, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 538 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
Interventions
- DRUG 851B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Why NCT00312286 stopped before completion
NCT00312286 is an interventional study that assigns participants to a tested intervention. The registered 538 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (305% higher).
The record links to 0 conditions, and to 1 intervention - of which 851B is the first listed.
NCT00312286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00312286 about?
NCT00312286 is a clinical study titled "Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.". The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
What is the current status of trial NCT00312286?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 538 participants. The study started on 2006-04. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00312286?
The interventions under investigation include: 851B (DRUG).
Who is sponsoring clinical trial NCT00312286?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00312286's enrollment target sits among peer trials
538 63rd of 2000 higher than 1,938 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia